EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genscript Biotech's enterprise value is HK$14,571 Mil.
Genscript Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,953 Mil. Therefore, Genscript Biotech's EV-to-EBITDA for today is -7.46.
The historical rank and industry rank for Genscript Biotech's EV-to-EBITDA or its related term are showing as below:
HKSE:01548'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -44.96 Med: -8.42 Max: 147.4
Current: -6.94
During the past 10 years, the highest EV-to-EBITDA of Genscript Biotech was 147.40. The lowest was -44.96. And the median was -8.42.
HKSE:01548's EV-to-EBITDA is ranked worse than 100% of 455
companies
in the Biotechnology industry
Industry Median: 10.21
vs HKSE:01548: -6.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Genscript Biotech EV-to-EBITDA Historical Data
The historical data trend for Genscript Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genscript Biotech's EV-to-EBITDA
For the Biotechnology subindustry, Genscript Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's EV-to-EBITDA falls into.
Genscript Biotech's current Enterprise Value is HK$14,571 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,953 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Genscript Biotech's PE Ratio for today is calculated as:
Genscript Biotech's share price for today is HK$12.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.355.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Genscript Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Genscript Biotech (HKSE:01548) Business Description
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01548 has been successfully added to your 